CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies

Publisher: La Merie Publishing
Pages: 20
Format: PDF
Product Line:
Monthly Tracking Reports
Product Code: LMBT0005
Release Date: October of 2016

200.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

CD123-Targeted Immunotherapeutics in:

September 2016 R&D and Business Tracker for Bispecific Antibodies

This pdf report contains information about Bispecific Antibodies released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Bispecific Antibodies.

Featured presentations of September 2016 include the pipeline of CD123-targeted immunotherapeutics, the profile of Swiss pharmaceutical company Neovii Pharmaceuticals and the bispecific antibody profile of AMV-564 from Amphivena Therapeutics.

The September 2016 issue of our R&D and Business Tracker service about Bispecific Antibodies covers;

  • T-Cell redirecting bispecific cancer antibodies
  • NK cell redirecting bispecific cancer antibodies
  • Bispecific immuno-oncology antibodies
  • Bispecific tumor antigens targeted cancer antibodies
  • Bispecific antibodies for inflammatory & autoimmune diseases
  • Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases

The monthly update report about Bispecific Antibodies contains:

R&D and Technology Tracker

  • Pipeline changes
  • Regulatory news
  • Technology validations
  • Manufacturing news

Business Tracker for:

  • Company updates
  • Collaboration
  • Licensing
  • Merger & acquisitions
  • Financing

Clinical Trial Tracker
Scientific Publication Tracker
Featured Bispecific Antibody Profile: AMV-564
Featured Company Profile: Neovii Pharmaceuticals
Featured Target or Technology Pipeline: CD123-Targeted Immunotherapeutics

CD123-Targeted Immunotherapeutics:

  • Antibody-Drug Conjugates
  • Immunotoxins
  • Fc-Engineered Antibodies
  • T-cell Redirecting Bispecific Antibodies
  • CAR T-Cells

Information about the CD123-Targeted Immunotherapeutics pipeline is provided in a tabular format and fully referenced.

Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.

Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.

Contact us at publishing@lamerie.com to discuss your needs and our ideas of fulfilling them.

 


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top